Duyuru • Mar 23
Wacker Chemie AG, Annual General Meeting, May 06, 2026 Wacker Chemie AG, Annual General Meeting, May 06, 2026, at 10:00 W. Europe Standard Time. Reported Earnings • Mar 12
Full year 2025 earnings released: €16.53 loss per share (vs €4.85 profit in FY 2024) Full year 2025 results: €16.53 loss per share (down from €4.85 profit in FY 2024). Revenue: €5.49b (down 4.1% from FY 2024). Net loss: €821.1m (down 441% from profit in FY 2024). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance. New Risk • Mar 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 92% Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Profit margins are more than 30% lower than last year (0.4% net profit margin). New Risk • Nov 07
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.4% Last year net profit margin: 2.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 92% Paying a dividend despite having no free cash flows. Minor Risk Profit margins are more than 30% lower than last year (0.4% net profit margin). Duyuru • Sep 22
Wacker Chemie AG(XTRA:WCH) dropped from FTSE All-World Index (USD) Wacker Chemie AG(XTRA:WCH) dropped from FTSE All-World Index (USD) New Risk • Aug 03
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 92% The company is paying a dividend despite having no free cash flows. Dividend yield: 3.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 01
Second quarter 2025 earnings released: €0.49 loss per share (vs €0.48 profit in 2Q 2024) Second quarter 2025 results: €0.49 loss per share (down from €0.48 profit in 2Q 2024). Revenue: €1.41b (down 3.7% from 2Q 2024). Net loss: €19.2m (down 166% from profit in 2Q 2024). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance. Reported Earnings • May 02
First quarter 2025 earnings released: €0.16 loss per share (vs €0.89 profit in 1Q 2024) First quarter 2025 results: €0.16 loss per share (down from €0.89 profit in 1Q 2024). Revenue: €1.48b (flat on 1Q 2024). Net loss: €7.90m (down 118% from profit in 1Q 2024). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 4.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 46 percentage points per year, which is a significant difference in performance. Upcoming Dividend • May 02
Upcoming dividend of €2.50 per share Eligible shareholders must have bought the stock before 08 May 2025. Payment date: 12 May 2025. Payout ratio is a comfortable 52% but the company is not cash flow positive. Trailing yield: 3.8%. Lower than top quartile of British dividend payers (6.0%). Lower than average of industry peers (4.6%). Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €65.75, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 10x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 50% over the past three years. Duyuru • Mar 25
Wacker Chemie AG, Annual General Meeting, May 07, 2025 Wacker Chemie AG, Annual General Meeting, May 07, 2025, at 10:00 W. Europe Standard Time. New Risk • Mar 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.0% average weekly change). Declared Dividend • Mar 14
Dividend reduced to €2.50 Dividend of €2.50 is 17% lower than last year. Ex-date: 2nd May 2025 Payment date: 6th May 2025 Dividend yield will be 3.0%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (52% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 53% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 13
Full year 2024 earnings released: EPS: €4.85 (vs €6.31 in FY 2023) Full year 2024 results: EPS: €4.85 (down from €6.31 in FY 2023). Revenue: €5.72b (down 11% from FY 2023). Net income: €241.0m (down 23% from FY 2023). Profit margin: 4.2% (down from 4.9% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 4.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Duyuru • Mar 13
Wacker Chemie AG announces Annual dividend, payable on May 06, 2025 Wacker Chemie AG announced Annual dividend of EUR 2.5000 per share payable on May 06, 2025, ex-date on May 02, 2025 and record date on May 05, 2025. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €76.45, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 10x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 38% over the past three years. Reported Earnings • Oct 29
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: €1.49b (down 2.2% from 3Q 2023). Net income: €44.2m (up 58% from 3Q 2023). Profit margin: 3.0% (up from 1.8% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 6.5% decline forecast for the Chemicals industry in the United Kingdom. Valuation Update With 7 Day Price Move • Oct 03
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €93.67, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 13x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 28% over the past three years. Reported Earnings • Jul 28
Second quarter 2024 earnings released: EPS: €0.58 (vs €2.38 in 2Q 2023) Second quarter 2024 results: EPS: €0.58 (down from €2.38 in 2Q 2023). Revenue: €1.47b (down 16% from 2Q 2023). Net income: €29.0m (down 75% from 2Q 2023). Profit margin: 2.0% (down from 6.7% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 6.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: €0.89 (vs €2.90 in 1Q 2023) First quarter 2024 results: EPS: €0.89 (down from €2.90 in 1Q 2023). Revenue: €1.49b (down 15% from 1Q 2023). Net income: €44.2m (down 69% from 1Q 2023). Profit margin: 3.0% (down from 8.3% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 2.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 7% per year. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: €0.56 (vs €5.08 in 3Q 2022) Third quarter 2023 results: EPS: €0.56 (down from €5.08 in 3Q 2022). Revenue: €1.52b (down 29% from 3Q 2022). Net income: €33.5m (down 87% from 3Q 2022). Profit margin: 2.2% (down from 12% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. New Risk • Jul 31
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.9% Last year net profit margin: 17% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 7.6% per year for the foreseeable future. Minor Risks Dividend is not well covered by cash flows (130% cash payout ratio). Profit margins are more than 30% lower than last year (9.9% net profit margin). Reported Earnings • Jul 30
Second quarter 2023 earnings released: EPS: €2.38 (vs €7.67 in 2Q 2022) Second quarter 2023 results: EPS: €2.38 (down from €7.67 in 2Q 2022). Revenue: €1.75b (down 19% from 2Q 2022). Net income: €118.1m (down 69% from 2Q 2022). Profit margin: 6.7% (down from 18% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Duyuru • Jul 21
Wacker Chemie AG Lowers Sales Guidance for the Year 2023 Wacker Chemie AG lowered sales guidance for the year 2023. The company now has the following expectations: Group sales for 2023 are likely to come in between EUR 6.5 billion and EUR 6.8 billion (previous guidance: between EUR 7 billion and EUR 7.5 billion). Upcoming Dividend • May 12
Upcoming dividend of €12.00 per share at 8.6% yield Eligible shareholders must have bought the stock before 19 May 2023. Payment date: 23 May 2023. Payout ratio is a comfortable 48% and the cash payout ratio is 85%. Trailing yield: 8.6%. Within top quartile of British dividend payers (5.8%). Higher than average of industry peers (2.3%). Duyuru • May 10
Wacker Chemie AG acquired Biotechnology Assets, S.A from Kartesia Advisor LLP for €100 million. Wacker Chemie AG acquired Biotechnology Assets, S.A from Kartesia Advisor LLP for €100 million on May 5, 2023. WACKER will continue and grow existing customer relationships maintained by ADL BioPharma in its capacity as CMO for fermentation-based products for the food, pharmaceutical and consumer goods industries.
Wacker Chemie AG completed the acquisition of Biotechnology Assets, S.A from Kartesia Advisor LLP on May 5, 2023. Reported Earnings • Mar 16
Full year 2022 earnings released: EPS: €25.18 (vs €16.24 in FY 2021) Full year 2022 results: EPS: €25.18 (up from €16.24 in FY 2021). Revenue: €8.21b (up 32% from FY 2021). Net income: €1.25b (up 55% from FY 2021). Profit margin: 15% (up from 13% in FY 2021). The increase in margin was driven by higher revenue. Revenue is expected to decline by 2.2% p.a. on average during the next 3 years, while revenues in the Chemicals industry in the United Kingdom are expected to grow by 2.0%. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 65% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 12
Investor sentiment improved over the past week After last week's 18% share price gain to €132, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 19x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 115% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €124 per share. Buying Opportunity • Nov 09
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 26%. The fair value is estimated to be €143, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 102%. Revenue is forecast to decline by 11% in 2 years. Earnings is forecast to decline by 56% in the next 2 years. Valuation Update With 7 Day Price Move • Sep 19
Investor sentiment deteriorated over the past week After last week's 15% share price decline to €130, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 17x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 113% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €201 per share. Reported Earnings • Aug 03
Second quarter 2022 earnings released: EPS: €7.66 (vs €3.69 in 2Q 2021) Second quarter 2022 results: EPS: €7.66 (up from €3.69 in 2Q 2021). Revenue: €2.17b (up 45% from 2Q 2021). Net income: €371.8m (up 112% from 2Q 2021). Profit margin: 17% (up from 12% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 1.1% compared to a 20% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Jul 06
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 19%. The fair value is estimated to be €161, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.3% over the last 3 years. Earnings per share has grown by 76%. Revenue is forecast to grow by 3.9% in 2 years. Earnings is forecast to decline by 42% in the next 2 years. Upcoming Dividend • May 16
Upcoming dividend of €8.00 per share Eligible shareholders must have bought the stock before 23 May 2022. Payment date: 25 May 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 5.1%. Within top quartile of British dividend payers (4.9%). Higher than average of industry peers (2.7%). Reported Earnings • May 02
First quarter 2022 earnings released: EPS: €7.92 (vs €2.06 in 1Q 2021) First quarter 2022 results: EPS: €7.92 (up from €2.06 in 1Q 2021). Revenue: €2.08b (up 53% from 1Q 2021). Net income: €402.6m (up 278% from 1Q 2021). Profit margin: 19% (up from 7.8% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.8% compared to a 16% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 18
Full year 2021 earnings: Revenues in line with analyst expectations Full year 2021 results: Revenue: €6.21b (up 32% from FY 2020). Net income: €806.9m (up 327% from FY 2020). Profit margin: 13% (up from 4.0% in FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 7.9% compared to a 11% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 26% per year whereas the company’s share price has increased by 24% per year. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment improved over the past week After last week's 18% share price gain to €151, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 20x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 85% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €124 per share. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €123, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 23x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 46% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €189 per share. Reported Earnings • Oct 30
Third quarter 2021 earnings released: EPS €4.90 (vs €1.30 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €1.66b (up 40% from 3Q 2020). Net income: €248.7m (up 267% from 3Q 2020). Profit margin: 15% (up from 5.7% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • May 06
Upcoming dividend of €2.00 per share Eligible shareholders must have bought the stock before 13 May 2021. Payment date: 17 May 2021. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (4.1%). In line with average of industry peers (1.6%). Reported Earnings • May 02
First quarter 2021 earnings released: EPS €2.06 (vs €1.31 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €1.36b (up 14% from 1Q 2020). Net income: €106.6m (up 55% from 1Q 2020). Profit margin: 7.8% (up from 5.8% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 18
Full year 2020 earnings released The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: €4.69b (down 4.8% from FY 2019). Net income: €189.2m (up €831.8m from FY 2019). Profit margin: 4.0% (up from net loss in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Feb 03
New 90-day high: €128 The company is up 57% from its price of €81.24 on 04 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €57.79 per share.